Clinical Trials for Non-Small Cell Lung Cancer

CAFs (Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC): a Phase I/II Study

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with stage IV or recurrent NSCLC who have progressed after prior systemic therapy (including PD-1/PD-L1 inhibitors) and lack EGFR, ALK, or ROS1 mutations, to receive atezolizumab (PD-L1 inhibitor) plus pirfenidone, an antifibrotic agent with immunomodulatory properties. Suitable patients should have adequate organ function, ECOG 0-2, and no significant comorbidities or prior severe pneumonitis.

ClinicalTrials.gov ID: NCT04467723

Local Consolidative Therapy (LCT) and Durvalumab (MEDI4736) for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy (ENDURE)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with stage III NSCLC who have oligoprogressive (≤3 lesions) or polyprogressive (>3 lesions) disease after prior chemoradiation and anti-PD-L1 therapy, treating them with local consolidative therapy (radiation and/or surgery) plus durvalumab (an anti-PD-L1 antibody), with polyprogressive patients also receiving platinum-based chemotherapy. Patients with EGFR or ALK alterations and standard targeted options are excluded.

ClinicalTrials.gov ID: NCT04892953

TH-138: Phase II Randomized Trial of Carboplatin + Pemetrexed + Bevacizumab, With or Without Atezolizumab in Stage IV Non-squamous NSCLC Patients Who Harbor a Sensitizing EGFR Mutation or Have Never Smoked

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with stage IV non-squamous NSCLC who have either a sensitizing EGFR exon 19 or 21 mutation (after progressing on TKI therapy) or never smokers with wild-type tumors and randomizes them to standard carboplatin, pemetrexed, and bevacizumab with or without atezolizumab, a PD-L1 immune checkpoint inhibitor. Maintenance therapy consists of pemetrexed and bevacizumab, with or without atezolizumab per treatment arm.

ClinicalTrials.gov ID: NCT03786692

A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant CfDNA in Plasma After Initiation of Osimertinib

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: Eligible patients are adults with metastatic non-small cell lung cancer harboring activating EGFR mutations who have persistent EGFR-mutant ctDNA in plasma after initial osimertinib treatment. The trial compares continuation of osimertinib (a third-generation irreversible EGFR TKI) alone versus osimertinib combined with carboplatin and pemetrexed chemotherapy.

ClinicalTrials.gov ID: NCT04410796

IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib with Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

HealthScout AI summary: This trial enrolls adults with advanced, EGFR-mutated non-squamous NSCLC—either after progression on prior EGFR TKI therapy or with persistent mutant ctDNA on front-line osimertinib—to receive a combination of osimertinib and carotuximab, a monoclonal antibody targeting endoglin (CD105) to inhibit tumor angiogenesis. Eligible patients may have stable or treated brain metastases and must have measurable disease and available tumor tissue or willingness to undergo biopsy.

ClinicalTrials.gov ID: NCT05401110

An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with untreated, unresectable, locally advanced or metastatic non-squamous NSCLC harboring HER2 exon 19 or 20 mutations and randomizes them to trastuzumab deruxtecan—an antibody-drug conjugate targeting HER2—or standard platinum chemotherapy with pembrolizumab and pemetrexed. Eligible patients must have ECOG performance status 0-1 and be candidates for systemic therapy.

ClinicalTrials.gov ID: NCT05048797

Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (CD40L TIL) for Patients With Oncogene-Driven Advanced Non-Small Cell Lung Cancer (NSCLC)

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with stage IV or recurrent NSCLC harboring EGFR, ALK, ROS1, or HER2 alterations, who have progressed after appropriate targeted and systemic therapy (excluding prior PD-1/PD-L1 inhibitors). Patients receive CD40L-augmented tumor-infiltrating lymphocytes (TILs), which are designed to enhance T-cell activation, in combination with nivolumab following lymphodepleting chemotherapy and interleukin-2 support.

ClinicalTrials.gov ID: NCT05681780

Phase II Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-Small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls adults with metastatic or unresectable NSCLC and ECOG performance status 0-2 (excluding those with actionable mutations or significant comorbidities) to receive standard first-line chemoimmunotherapy regimens, including pembrolizumab (anti-PD-1 antibody) plus histology- and PD-L1–guided platinum-doublet chemotherapy, comparing efficacy and safety outcomes between PS 2 and PS 0-1 patients.

ClinicalTrials.gov ID: NCT04253964

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Advanced KRAS Mutated Non-Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial is enrolling patients with unresectable stage III/IV non-small cell lung cancer harboring specific KRAS mutations (G12C, G12V, G12D, G12A, G13D, or G12R) who have not had prior therapy for advanced disease, to evaluate a KRAS-targeted long peptide vaccine (designed to elicit immune responses against mutant KRAS) combined with poly-ICLC adjuvant, nivolumab (PD-1 inhibitor), and ipilimumab (CTLA-4 inhibitor). Key exclusions include prior immunotherapy, active autoimmune disease, and untreated or symptomatic brain metastases.

ClinicalTrials.gov ID: NCT05254184

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

HealthScout AI summary: This trial enrolls treatment-naïve adults with metastatic, sensitizing EGFR-mutant (non-exon 20 insertion) non-squamous NSCLC (stage IIIB-IV/recurrent, ECOG 0-2) to compare osimertinib (a third-generation EGFR TKI) alone versus in combination with bevacizumab, an anti-VEGF antibody, as first-line therapy. Patients must be eligible for anti-VEGF treatment and have measurable disease.

ClinicalTrials.gov ID: NCT04181060